Login to Your Account

Tarceva Survival Data Intensify Lung Cancer Maintenance Battle

By Trista Morrison

Tuesday, July 14, 2009
It's been barely a week since Eli Lilly and Co.'s chemotherapy drug Alimta (pemetrexed) received the first-ever FDA approval in the maintenance treatment of lung cancer, and already the competition is closing in. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription